UB, WNY women played major role

Posted on

By ELLEN GOLDBAUM
Published: June 9, 2011

Saturday’s announcement at the annual meeting of the American Society of Clinical Oncology that the drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women is the result of an international, randomized double-blind phase III clinical trial in which UB researchers and hundreds of Western New York women played a critical role.

The findings can be viewed online in the New England Journal of Medicine.

More than 500 Western New York women participated in the study, according to Jean Wactawski-Wende, principal investigator of the Buffalo ExCel clinical center, co-author of the manuscript, and professor and associate chair of the Department of Social and Preventive Medicine, School of Public Health and Health Professions.

(Read more here)

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s